Zacks Rating on Chimerix (CMRX)

Chimerix (CMRX) has an average broker rating of 2.91, which is interpreted as a Hold, as rated by 8 equity analysts. Nonetheless, 1 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 6 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold. 1 brokerage firm advices Strong Sell on the share due to lack of confidence about the future of the company.

Chimerix (CMRX) : Currently there are 7 street experts covering Chimerix (CMRX) stock. The most bullish and bearish price target for the stock is $12 and $5 respectively for the short term. The average price target of all the analysts comes to $7.29. The estimated standard deviation from the target is $2.29.


Shares of Chimerix, Inc. rose by 5.54% in the last five trading days and 17.24% for the last 4 weeks. Chimerix, Inc. is up 0.42% in the last 3-month period. Year-to-Date the stock performance stands at -46.82%. Chimerix (NASDAQ:CMRX): stock turned positive on Tuesday. Though the stock opened at $4.73, the bulls momentum made the stock top out at $4.83 level for the day. The stock recorded a low of $4.61 and closed the trading day at $4.76, in the green by 1.06%. The total traded volume for the day was 585,380. The stock had closed at $4.71 in the previous days trading.

Chimerix, Inc. a biopharmaceutical company dedicated to discovering, developing and commercializing oral antivirals. The Companys lipid conjugate technology has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development. It is clinical-stage nucleotide analog lipid-conjugate which has demonstrated potent antiviral activity and safety in convenient, orally administered dosing regimens. In addition, it has an active discovery program focusing on viral targets. CMX157, is its second clinical-stage nucleotide analog, uses the same lipid technology as brincidofovir to deliver high intracellular concentrations of the potent antiviral drug, tenofovir. Tenofovir, marketed under the brand name Viread and in multiple fixed-dose combinations, is used for the treatment of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. It has discovered, developed and selected a clinical candidate, CMX669, for BK virus and cytomegalovirus (CMV).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.